Covid-19 News

    Of cause she did consult with a doctor, expert with such issues, and did not do any self treatment. It is also telling that the side effect was never reported, so if doctors do not report all issues how could we know if they are commonly enough to be a problem. After all the issue was nasty but not a severe life threatening side effect, and those are much less likely to be reported. Personally I think the jab was contaminated, but she also has a very strong immune system and is otherwise never sick even when we had small children.

    I did state that it was anecdotal and with that came the needed warning to not take it as a fact, I can't help that you guy's do not want to pay for a decent education of your people and then treating them like trash wining about how stupid they are - you know that proper education would stop 90% of them from miss understand proper communication like I just presented and fall for the latest craze- yeah I know, you do want people to be treated more nicely, but you get my point, you as a country get what you pay for. (we are heading in the same direction though with tax cuts and a drift towards a US like system unfortunately because more and more people here just care for themselves)

    St. Peter’s Hospital Staff Report Harassment From State Officials After not Providing Patient with Ivermectin


    St. Peter’s Hospital Staff Report Harassment From State Officials After not Providing Patient with Ivermectin
    The politics in Big Sky Country may deviate a little from coastal urban centers. With a libertarian-minded Governor, the politics in Montana favor medical
    trialsitenews.com


    The politics in Big Sky Country may deviate a little from coastal urban centers. With a libertarian-minded Governor, the politics in Montana favor medical freedom and physician and patient choice. Do hospitalized COVID-19 patients have a right to access ivermectin if their physicians prescribe the FDA-approved product off-label? In previous times, this typically wouldn’t be a problem. But in the COVID-19 era, an unprecedented centralization of medical care finds health systems and hospitals strictly following federal guidelines, whether that be the U.S. Food and Drug Administration (FDA) or the Centers for Disease Control and Prevention (CDC), for example. TrialSite has followed numerous court cases where hospitalized COVID-19 patient family members use the court systems to compel a particular hospital to treat the family member with ivermectin after the hospital’s protocol has failed. In most parts of the country, state officials wouldn’t bother to get involved and simply defer to the health system or federal edict. Not in Big Sky Country, the western state of Montana, where patient-centric medical choice becomes a hot topic. Most recently, the leadership of Helena-based St. Peters Health complained that at least three high-ranking Montana state officials threatened and harassed hospital doctors who had previously refused to treat patients with ivermectin.


    Welcome to Big Sky Country

    As reported in local media, St. Peter’s Health opted not to disclose the official names in their statement. Attorney General Austin Knudsen shared that he reached out to the hospital.


    According to the Daily Beast, Theresa Manzella, a Republican in the State Senate, confirmed she has communicated with the health system via an online form but denied making any threats.


    Montana’s politics have become more libertarian with the election of multimillionaire tech entrepreneur Greg Gianforte. Embracing a pro-medical freedom agenda, Gianforte was the founder of Bozeman-based RightNow Technologies, which Oracle acquired for $1.5 billion. Gianforte sponsored a law that ensures that the unvaccinated cannot be treated differently in the state.


    The St. Peters Situation

    As reported in Montana news, St. Peter’s came out with a statement declaring, “St. Peter’s Health works closely with public officials and regulatory agencies, and we occasionally receive inquiries about patient care and patient rights. Last week, several of our providers and care team members who are working tirelessly at the bedside were harassed and threatened by three public officials.”


    “These officials have no medical training or experience, yet they were insisting our providers give treatments for COVID-19 that are not authorized, clinically approved, or within the guidelines established by the FDA and the CDC. In addition, they threatened to use their position of power to force our doctors and nurses to provide this care. These conversations were deeply troubling to our physicians and staff because they were threatened and their clinical judgment was called into question by these individuals.”


    Patient & Family vs. Health System

    “The most typical scenario we report on involves family members that will do anything to save a loved one in the hospital,” reports Daniel O’Connor, TrialSite Founder. O’Connor continued that “most frequently, the hospitals are receiving funding from the federal government and are following implicit instructions not to include treatments such as ivermectin.”


    “So they [the patient’s family] go find specialized legal counsel and file an action in the courts to compel the hospital to treat their family member with ivermectin,” the TrialSite founder continued. “Several months ago, judges were siding with the patients, but with mounting anti-ivermectin pressure from the federal government, that dynamic has most certainly changed in favor of the hospital or health system.”


    The health systems make an important point that they cannot stand for courts meddling in the practice of medicine in their hospital or health system. But what if the hospital’s protocol fails and the patient is dying? TrialSite’s O’Connor inserted in that situation, “Shouldn’t there be a collective consensus to do whatever is feasible to save that patient’s life?”


    Senator Manzella concurred, “If someone is at death’s door and they’re circling the drain, why wouldn’t you allow them their wishes?” Manzella told the publication. “If I as an adult of sound mind want to take responsibility for my own healthcare if I get this terrible virus, I think I should have that opportunity as a free American adult.”


    Hospital Response

    In response, St. Peter’s—which, according to reports, has strict visitation policies in place for preventative measures—issued a statement strongly disputing these accusations. St. Peter’s spokesperson Katie Gallagher insisted that the hospital administration has “reviewed all medical and legal records related to these incidents, and we have verified that our teams are providing care in accordance with clinical best practice, hospital policy, and patient rights. Any allegations or assertions otherwise are unfounded.”


    About St. Peter’s Hospital

    St. Peter’s Hospital is a nonprofit health care system based in Helena, Montana. With a 99-bed acute care hospital, physician clinics, cancer treatment center, 24-bed behavioral health unit, urgent care clinics, home health, and hospice care, the health system also includes a dialysis center and ambulance services.


    The hospital and health center serves a largely rural area with 97,000 residents in the five counties of Lewis and Clark, Broadwater, Powell, Meagher, and Jefferson. For more information on COVID care there, see the link.


    COVID-19 information: Non-COVID-19 and non-flu-like care options | St. Peter's Health

    I now that the vaccine production is very strictly controlled, but when the vaccine enters here it goes to labs around the country

    where from one jabs package one could make multiple jabs. If I understand this properly, this was not all that much automated and

    not as strictly controlled as in a production facility. We did in the first half year not get enough vaccines to vaccinate people so there

    was a lot of effort to get the most out of the stuff coming in. In all this meant that the contamination risk was much higher with the covid

    vaccine here than for essentially all other vaccines that people get.

    Quote from Fm1

    St. Peter’s spokesperson Katie Gallagher insisted that the hospital administration has “reviewed all medical and legal records related to these incidents, and we have verified that our teams are providing care in accordance with clinical best practice, hospital policy, and patient rights. Any allegations or assertions otherwise are unfounded.”

    Here you only can learn how deeply teh FM/R/ :( /B mafia undermined the US health system. It's a top down mafia state inside the other mafia state....


    Quote from stefan

    I now that the vaccine production is very strictly controlled, but when the vaccine enters here it goes to labs around the country

    where from one jabs package one could make multiple jabs.

    The problem is that e.g. Pfizer contains 30% crap RNA of unknown structure. This happens if you - the untalented chemists at Biontec.. - take a monoclonal cancer chemo and reprogram it a few months for a vaccine like effect.


    One thing to do before you take a vaccine. Do an antibody test or you will suffer from ADE. 0=zero need for a vaccine if you have antibodies!

    So I hope she at least got Moderna!

    Rogan’s Exposure of CNN & Washington Post’s Moment of Clarity & Sanjay True Value System


    Rogan’s Exposure of CNN & Washington Post’s Moment of Clarity & Sanjay True Value System
    The Washington Post carried an interesting opinion piece on October 21st by their media critic, Eric Wemple, discussing a three-hour interview podcast Joe
    trialsitenews.com



    The Washington Post carried an interesting opinion piece on October 21st by their media critic, Eric Wemple, discussing a three-hour interview podcast Joe Rogan did with CNN’s Medical Correspondent Sanjay Gupta. The interview most certainly became heated when Rogan confronted Gupta about the fact that Rogan took ivermectin to combat his bout with Covid-19. As reported by TrialSite, Rogan put Gupta in a corner where he had to confess that CNN behaved badly. “It’s a lie. It’s a lie on a news network and it’s a lie … that they’re conscious of. This is not a mistake,” said Rogan. Gupta went on to acknowledge his employer’s bad behavior but quickly flipped his position, most certainly in a quest to keep his position and salary.


    The Lie

    CNN has repeatedly referred to ivermectin as a medicine to deworm horses and not to be used in humans. It’s true that ivermectin started as a veterinary drug, but it became a viable medication for humans. The man who discovered ivermectin, Satoshi Omura, has referred to ivermectin as a “wonder drug for humans” that “improves life.”


    Information in the mainstream media regarding ivermectin has been skewed. Omura and another scientist, William C. Campbell, were awarded the Nobel Prize in 2015 for creating ivermectin and “for their discoveries concerning a novel therapy against infections caused by roundworm parasites.” However, several physicians recently have started using and prescribing ivermectin in low doses to treat the early stages of covid. Over 60 studies to date have used ivermectin to address covid—most of them successfully.


    In several trials, ivermectin was found to reduce the risk of death of covid. In a study in Australia, 600 patients were treated within two days after testing positive using Ivermectin Triple Therapy (ITT). The outcome was significant in that none of the 600 died and all recovered. The result of the Australian study is that ITT is a viable treatment for early-onset of covid, but this has not been reported in the mainstream American media.


    Merck donates billions of doses of ivermectin to help eradicate river blindness via the Mectizan program. Ivermectin has been used for scabies as well, but the Food and Drug Administration doesn’t recommend it as a remedy to combat covid. The difference between ivermectin for humans and ivermectin for horses is the amount of the dosage. And therein lies the danger.


    TrialSite News has done extensive reporting on ivermectin and published a Fact Sheet report on the drug, which evaluated why and why not ivermectin hasn’t been readily available.


    According to The Washington Post, CNN has deliberately pushed the idea that ivermectin is dangerous for human consumption. CNN hosts, Erin Burnett, Anderson Cooper, Don Lemon, and Jim Acosta have repeatedly accused Rogan of pushing an anti-vax position and claimed Rogan “raided the barnyard to be treated for covid.”


    In the article, the CNN hosts “turn up a consistent formulation from multiple CNN voices that surely wasn’t a sober recitation of the facts. By highlighting that ivermectin is a horse dewormer, and downplaying that ivermectin has important uses for people, CNN facilitates a certain assumption among its viewers. Namely, that Rogan had been haunting the aisles of Tractor Supply.”


    Back to the original Rogan and Gupta back and forth, Gupta finally admitted the CNN hosts “shouldn’t have said that.”


    CNN followed up with a statement defending the views of its hosts, saying that Rogan was “sowing doubt to his listeners about the effectiveness of proven and approved science of vaccines.”


    Does CNN project its hosts’ views on others?

    Gupta later went on with CNN’s Don Lemon and essentially backtracked his remarks on the Rogan podcast. This was an unfortunate move by the network’s top doctor done so he could keep his elite lifestyle. Lemon, whose credibility as a journalist continues to decline, pointed out that ivermectin is a horse dewormer, hasn’t been approved by the FDA for human consumption, and has not been cleared as a treatment for covid. Gupta agreed, adding it was probably Rogan’s monoclonal antibody treatment that got him over covid. Gupta went on to push his current book—which again is what Gupta seemingly most cares about—money, fame, and recognition.


    The Washington Post pointed out that it is true that Joe Rogan has questioned vaccines on his podcast, but the significance of the Washington Post article is that CNN and other mainstream news outlets consistently deride Fox News for spreading disinformation about covid. In this instance, isn’t CNN doing the same thing


    https://www.washingtonpost.com/opinions/2021/10/21/joe-rogan-cnn-ivermectin-statement-gupta/

    The U.S. Health Feds’ Effort to Purge Ivermectin Use is Working


    The U.S. Health Feds’ Effort to Purge Ivermectin Use is Working
    Recently, TrialSite reached out to 100 pharmacies in a survey investigating whether ivermectin would be available. Many readers have sent us tips that the
    trialsitenews.com


    Recently, TrialSite reached out to 100 pharmacies in a survey investigating whether ivermectin would be available. Many readers have sent us tips that the supply of the drug was suddenly in very short supply. While ivermectin prescriptions skyrocketed by summer for off-label use driven by COVID-19, there were no pervasive reports of shortage or availability issues then. After reaching out to 100 pharmacies, TrialSite reports nearly 65% of them suddenly have major “supply issues” informing our analysts that the product was out and on backorder.


    Prescriptions for ivermectin absolutely skyrocketed to nearly 90,000 prescriptions per week, reported the New York Times last month even though the drug purportedly didn’t help address early-onset mild-to-moderate COVID-19. By October, TrialSite suggests increasing pressure from pharmacy and physician licensing boards on providers to not prescribe the drug for off-label use led to sweeping changes in access. Of course, the pressure comes from above as the current Biden administration, leadership within the National Institutes of Health and the U.S. Food and Drug Administration (FDA), and the media have vilified the drug when it comes to any off-label use for COVD-19.


    Earlier in the year, this cheap drug was far easier to obtain via physician prescription. But many TrialSite readers called or emailed tips that they are not able to access the drug—even with a physician’s prescription.


    Typically, an easy product to access with a prescription, our survey indicates most pharmacies now will declare that they do not have the product available. Many of the pharmacies that we spoke with reported that even their wholesalers, such as Amerisource and McKesson, reported supply issues.


    We identified some geographic patterns. For example, the 25% of pharmacies that did report some availability of ivermectin were mostly based in the South or the Southwest. Conversely, those pharmacies we surveyed in the Northeast or Midwest, for example, were far more likely to report “out of supply” and in “backorder” status with no foreseeable date to obtain it. Overall, we learned that if the prescription was for COVID-19, it is now far more difficult to get that prescription filled.


    The standard price point for ivermectin, according to Drugs.com, for 20 tablets 3mg ivermectin is $93.97 or $4.70 per unit. During our survey, we found a range of prices much higher than the Drugs.com average price. Some pharmacies are willing to provide the drug off-label for cash, but of course, a prescription is needed. For example, one pharmacy in Dallas, Texas, offers a 20-pill box for $199 or $9.95 per pill! We found another location in Delaware charging $5.46 per pill. A pharmacy in Louisiana charged $4.50 per tablet, one in Alabama quoted us $5.89 per pill, and a private pharmacy in Phoenix was charging $6 per pill. We found a few more cases where the price per unit headed toward the $9 mark.


    Of note, we discovered that overwhelmingly, large corporate chains have effectively cut off the ivermectin supply, declaring they cannot access the drug. They reported it was on “backorder,” while small, privately-owned pharmacies in the South and Southwest were more likely to carry the product but charge increasingly exorbitant prices.


    FLCCC Pharmacy List


    Recently, the Front Line COVID-19 Critical Care Alliance (FLCCC) shared their ivermectin pharmacy list. Demonstrating the purge that has occurred, only 39 pharmacies made the list out of about 88,000 pharmacies nationwide

    Quote from Shane D.

    but there was a repurposed drug safer than aspirin that many undeveloped countries were using with apparent great success, but it's use was banned in the developed countries because they wanted everyone to have no option but to take a partially effective vaccine instead, and were not even allowed to talk about it, much less promote it, on the major social media platforms....I would not have believed it. .

    And you would have been right. It is only in weird corners of the internet that any success is apparent (I know they seem very very large to those who read them!).

    Interesting new study based on 6.4 million Covid vaccinated and 4.6 million unvaccinated for Covid but vaccinated against the flu. [that's a BIG study with good stats]


    The Covid vaccinated people were less likely to die from Covid AND all other causes. In fact their death rate was only about 35% of the death rate of the non Covid vaccinated.


    Vaccinated People Less Likely to Die of Any Cause: Study | Newsmax.com
    findings published Oct. 22 in the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.

    Quote

    The Covid vaccinated people were less likely to die from Covid AND all other causes. In fact their death rate was only about 35% of the death rate of the non Covid vaccinated.

    It just points to fact, that vaccinated people generally care about their health more. Accounting this factor would paradoxically render real efficiency of vaccines even lower than it follows from statistics.

    Quote from Alan Smith

    The Covid vaccinated people were less likely to die from Covid AND all other causes. In fact their death rate was only about 35% of the death rate of the non Covid vaccinated.

    So one more confirmation that the CoV-19 vaccine protection is below 65%. This is the actual correct figure if you do not look at prior infections. If you add prior infection(s) protection drops to 20..30%.

    These figures only tell that people with a weak immune system really profit more than the claimed 65%!


    For healthy people the CoV-19 monoclonal gen therapy adds no more lasting protection than for a very short period. But the damage of the therapy can be gigantic.

    Quote from Fm1

    Some pharmacies are willing to provide the drug off-label for cash, but of course, a prescription is needed. For example, one pharmacy in Dallas, Texas, offers a 20-pill box for $199 or $9.95 per pill! We found another location in Delaware charging $5.46 per pill.

    As said: The FM/R/X/B mafia is just a common drug dealer network that is after the private profit for the godfathers .


    The ultimate prove that Ivermectin works is its depletion in the USA. Why do these cricket brains not understand that their action is 100% opposite to what they claim? IQ < 70??


    greed Q > 1 billion ??


    You have to tell privately everybody you know how disgusting the top (country wide & international) FM/R/X/B mafia members are. Fascists!

    Early COVID-19 treatments should not be ignored

    By Ben Carson & C. Boyden Gray


    Early COVID-19 treatments should not be ignored


    COVID-19 vaccines are not as effective in preventing infection and transmission as initially thought. Since we will have to live with COVID-19, it is vital that we stop suppressing the discussion of early treatment options for all patients, regardless of whether they have been vaccinated or not.


    The bulwark of opposition to repurposed drugs from public health officials, tech companies, academics, and the media has been astonishing. The shaming and erasing of clinicians who have actually healed patients with therapeutics has significantly damaged the public’s trust in medicine and scientific research.

    of the most striking examples of this was the infamous May 2020 Lancet paper that claimed hydroxychloroquine is dangerous to COVID-19 patients. It was based on faked data, and the journal retracted it, with the Lancet editor later dubbing that paper a "monumental fraud." There was this past summer’s reporting on ivermectin, with cable news and the CDC itself promoting the notion that it is strictly a veterinary medicine (it is not). It was also claimed that emergency rooms have been overwhelmed with Ivermectin overdose patients (they were not).


    Even YouTube, owned by Google, will not allow users to recommend hydroxychloroquine or ivermectin for COVID-19. They likewise prohibit claims that these drugs are effective or safe for treating COVID-19 patients.


    In reality, hydroxychloroquine, a 70-year-old drug used for malaria and autoimmune disorders, is safe enough to be taken by pregnant women. One need only review the work of Yale’s Dr. Harvey Risch about the effectiveness of hydroxychloroquine, and the number of lives it could have saved, to understand the tragic consequences of discrediting it.

    In 2015, William C. Campell and Satoshi Omura won the Nobel Prize in physiology or medicine for their discovery of avermectin and its compound ivermectin. It has saved millions worldwide from river blindness and elephantiasis. Since the spring of 2021, COVID-19 cases in India have plummeted in spite of a very low vaccination rate — a phenomenon the Washington Post described in September as a "mystery." In the Indian state of Uttar Pradesh, which has a population of 200 million people, they have made widespread use of ivermectin. COVID-19 cases appear to have been eliminated.


    The list of inexpensive repurposed early treatments is not limited to hydroxychloroquine and ivermectin. It includes antibiotics, antihistamines, and, notably, antioxidants and vitamins D and C and zinc, which boost the immune system. This is not misinformation.


    The latest addition to this list of disfavored therapeutics is monoclonal antibodies. It appears that the government may ration this life-saving treatment as a spur to raising vaccination rates. An anonymous Health and Human Services spokesman told the Washington Post that HHS will decide how much of the treatment different states will receive to "help maintain equitable distribution, both geographically and temporally" on a weekly basis.

    A Pfizer scientist secretly recorded by James O’Keefe’s Project Veritas said on tape that monoclonal antibodies were being "pushed to the side" because of "money," adding that this was “disgusting."


    It would, of course, be useful to be able to compare the breakthrough cases among the vaccinated with reinfection cases among those who have recovered from COVID-19 and have natural immunity. But no one knows the incidence of either type of infection. Rather than focusing so much time and energy on forcing even the naturally immune into submission, and further fraying society at the seams, we should turn our attention to therapeutic solutions for everyone who falls ill.


    Recently, there has been some excitement over the Merck antiviral pill. A study with 775 volunteers reportedly showed its use reduced the risk of COVID-19 hospitalization or death by half. But in July 2020, the press and public health officials, including Dr. Anthony Fauci, were almost uniformly dismissive of excellent studies conducted by the Henry Ford Health System in Detroit and the Mount Sinai Health System in New York, which showed a similar reduction in COVID-19 mortality with the use of hydroxychloroquine. Those observational studies included over 2,500 patients and over 6,000 patients, respectively.

    It's time to extend medical honesty beyond the scope of new, patented therapeutics. Those decades-old, safe, off-patent, inexpensive repurposed drugs that help patients should also be embraced.


    Dr. Carson, secretary of the Department of Housing and Urban Development from 2017 to 2021, is the founder of the American Cornerstone Institute. C. Boyden Gray has served as White House counsel, U.S. ambassador to the European Union and U.S. special envoy to Europe for Eurasian energy.

    קורונה - לוח בקרה


    Israel:: It looks like the CoV-19 figures did hit the bottom. The death figures are inconclusive as in the last few days more vaccinated age > 60 did die than unvaxx with about 60% vaccination over all and 84% in the age class. But death reporting is always 2 weeks late.


    But if no more unvaccinated die then this points to a severe (dis-) information problem or a high natural immunity!

    Scientists link Covid vaccines to rare neurological complications

    Study finds Pfizer and Oxford/AstraZeneca jabs have infrequent association with seven illnesses


    Covid vaccines associated with 7 rare neurological complications, says study


    The BioNTech/Pfizer and Oxford/AstraZeneca coronavirus vaccines are associated with seven rare neurological complications, according to the most comprehensive study of the side effects from the two jabs.




    Using data from 32m vaccinated adults in England, researchers estimated that an extra 38 people per 10m who received their first Oxford/AstraZeneca shot suffered from Guillain-Barré syndrome, which causes pain and weakness in the limbs and is usually temporary, than would do in the general population.

    They found an increased risk of haemorrhagic stroke, a brain bleed, in the 28 days after vaccination with the BioNTech/Pfizer shot, at an estimated 60 extra cases per 10m people. The increased risk was significantly higher in female patients.

    A smaller data set from Scotland backed up the association between the AstraZeneca vaccine and Guillain-Barré syndrome, but did not find the same link between the Pfizer shot and haemorrhagic stroke.


    Aziz Sheikh, professor of primary care research and development at the University of Edinburgh, emphasised that the adverse events were so rare that they had to report their incidence in millions, rather than thousands. The incidents were measured in the 28 days after vaccination, or a positive test result.


    “We’re not seeing a higher risk for any of these adverse events associated with the vaccine, than those associated with the infection,” he said.


    In fact, people infected with Sars CoV-2, the virus that causes Covid-19, had a substantially higher risk of the seven neurological conditions.


    The infection causes 145 excess cases of Guillain-Barré syndrome per 10m people, and 123 extra events of encephalitis meningitis and myelitis, inflammations of the brain and spinal cord. There was a higher risk of haemorrhagic stroke in people infected with the virus, but only for the first seven days after testing positive.


    The data covered people vaccinated from December-May and included 20m vaccinated with AstraZeneca and 12m who received a Pfizer jab, and were compared with 2m people who tested positive for Covid-19. The scientists will now study the incidence in the population after two doses.


    The AstraZeneca vaccine has become associated with another very rare blood-clotting side effect, leading some countries to abandon the shot or restrict its use in younger people. The mRNA vaccines from Pfizer and Moderna have been associated with a rare heart inflammation, especially in younger men.


    Julia Hippisley-Cox, professor of clinical epidemiology at the University of Oxford, who is not associated with the development of the Oxford/AstraZeneca vaccine, said that while the link with Guillain-Barré syndrome had been noted before this was the “largest, most reliable study internationally” of its kind.


    Pfizer said it took adverse events associated with its vaccine “very seriously”, collecting information to send to regulators. It added that “hundreds of millions of people around the world have been vaccinated with our vaccine”.


    AstraZeneca said patient safety was of the “utmost importance” and it worked with regulators to monitor safety information. Its coronavirus jab “has a similar safety profile to other vaccines and the [European Medicines Agency] and other international bodies including the WHO, have all stated the benefits of vaccination continue to outweigh any potential risks”.

    Why the CDC Ignores Natural Immunity


    Why the CDC Ignores Natural Immunity ⋆ Brownstone Institute
    There are many political reasons the CDC continues to ignore the scientific evidence on this issue. Here is a sampling
    brownstone.org


    The science on the efficacy and durability of natural immunity is now overwhelming. Yet the CDC continues to recommend lifting restrictions on the vaccinated but not those who have recovered from Covid and have superior natural immunity. Vaccine mandates across the country likewise ignore natural immunity simply because the CDC is ignoring it. Those promulgating vaccine mandates feel no need to actually address the science on this question; instead, they simply fall back on the CDC’s recommendation that everyone—regardless of immunity status—get vaccinated.


    There are many political reasons the CDC continues to ignore the scientific evidence on this issue. Here is a sampling of the reasons, which are neither compelling nor grounded in scientific findings:


    Public health officials worry that acknowledging natural immunity will lead people to deliberately try to get infected with Covid rather than getting vaccinated. The obvious response to this worry is that the natural immunity question is not about whether people should try to acquire natural immunity by deliberately getting infected; nobody is suggesting this. It is about the level of immunity afforded to those who have already recovered from Covid as compared to immunity from the vaccine.


    Public health officials worry that establishing whether a potential vaccine recipient has already had Covid is too inefficient and cumbersome: officials downplay anything that might slow the efficiency of vaccination campaigns or complicate the simplistic “needle in every arm” public messaging. The response to this worry is likewise straightforward. Vaccination centers need not take on the burden of testing prior to vaccination; simply place the burden of proof on the vaccine recipients. Some people with prior infection may still want the vaccine; as long as they are provided accurate information regarding risks and benefits of vaccines in this population, they are free to get vaccinated. For those with natural immunity who consider their individual risks and benefits and decide to decline vaccination, policies can specify that it’s their responsibility to establish prior immunity. Simply provide the option to them of presenting previous positive PCR test results, or obtaining antibody testing or a T-cell test (which remains positive after antibodies inevitably decline). While there are many other problems with vaccine passports, if officials insist upon them, at the very least these should be immunity passports rather than vaccine passports: this model has has already been implemented in several European countries.


    Public health officials worry that acknowledging natural immunity will amount to admitting the failure of their prior policies, which were implemented to slow or halt the spread of the virus. The two most basic numbers in immunology are incidence and prevalence: the former designates the rate of new cases over a given period of time, whereas the latter designates the rate of overall cases for a given period of time.


    Once the CDC acknowledges natural immunity, the obvious question is then about prevalence: how many Americans have already been infected with Covid since the pandemic began? That 20 months into the pandemic we don’t have an answer to this most basic question is astonishing, since it could easily be answered by randomly sampled population-based T-cell testing, or antibody testing sampled sequentially in a cohort every few months.


    If the CDC got back to epidemiological basics and finally did these essential studies, most scientists estimate that somewhere between 50% and 60% of the population will turn out to have natural immunity, including many who were vaccinated (which artificially elevates estimates of vaccine efficacy, by the way). In the mind of officials who never want to admit that they may have been wrong, this will suggest that—despite draconian lockdowns, social distancing, masking, scrubbing of surfaces, etc.—the virus nevertheless did what viruses do: over half of Americans got infected anyways.


    Self-interested public health agencies will see this as bad news. (The silver lining is that, of this huge number of people who have been infected with Covid, 99.8% will have survived, including 99.9996% of those under 50.)


    There are other political and financial considerations unduly influencing public policy agencies like the CDC on Covid policies, which I will explore in later posts. Against these non-scientific roadblocks, which have little to do with public health and sound policymaking, how can responsible scientists help move the needle on the CDC’s position? Can legal pressure be applied to require the CDC—in an open and publicly transparent manner—to examine the science on natural immunity and give credible reasons for their policies on this issue?


    In fact, precisely such legal pressure is already being applied, by a group of academic physicians and researchers (including yours truly) with the help of my team of lawyers at Siri & Glimstad.

    Evidence of transmission from fully vaccinated individuals in a large outbreak of the SARS-CoV-2 Delta variant in Provincetown, Massachusetts


    Evidence of transmission from fully vaccinated individuals in a large outbreak of the SARS-CoV-2 Delta variant in Provincetown, Massachusetts
    Multiple summer events, including large indoor gatherings, in Provincetown, Massachusetts (MA), in July 2021 contributed to an outbreak of over one thousand…
    www.medrxiv.org


    ABSTRACT

    Multiple summer events, including large indoor gatherings, in Provincetown, Massachusetts (MA), in July 2021 contributed to an outbreak of over one thousand COVID-19 cases among residents and visitors. Most cases were fully vaccinated, many of whom were also symptomatic, prompting a comprehensive public health response, motivating changes to national masking recommendations, and raising questions about infection and transmission among vaccinated individuals. To characterize the outbreak and the viral population underlying it, we combined genomic and epidemiological data from 467 individuals, including 40% of known outbreak-associated cases. The Delta variant accounted for 99% of sequenced outbreak-associated cases. Phylogenetic analysis suggests over 40 sources of Delta in the dataset, with one responsible for a single cluster containing 83% of outbreak-associated genomes. This cluster was likely not the result of extensive spread at a single site, but rather transmission from a common source across multiple settings over a short time. Genomic and epidemiological data combined provide strong support for 25 transmission events from, including many between, fully vaccinated individuals; genomic data alone provides evidence for an additional 64. Together, genomic epidemiology provides a high-resolution picture of the Provincetown outbreak, revealing multiple cases of transmission of Delta from fully vaccinated individuals. However, despite its magnitude, the outbreak was restricted in its onward impact in MA and the US, likely due to high vaccination rates and a robust public health response.


    DISCUSSION

    The outbreak of SARS-CoV-2 in Provincetown during and after the July 4th weekend was the first large outbreak of the Delta variant in a highly vaccinated population in the US. The robust public health response permitted extensive epidemiological and genomic characterization of the outbreak, the structure of transmission within it, and the role of vaccinated individuals, and offers generalizable insights for containing future outbreaks of Delta and other highly transmissible lineages of SARS-CoV-2.


    The Provincetown outbreak raised public health concern and attracted international attention primarily due to the prevalence of symptomatic breakthrough infections and the potential occurrence of transmission from vaccinated individuals. Consistent with other recent reports13,14, breakthrough infections with Delta, while often symptomatic and with moderate to high viral loads, were typically mild. Confidently assigning transmission links between individuals was unusually challenging: conventional contact tracing was difficult because of the many locations with dense potential contacts involved, while genomic inference of transmission was hindered by the low overall genetic diversity and large fraction of identical genomes. Nonetheless, using genomic data to prioritize plausible connections between samples followed by more detailed epidemiological investigation identified several likely instances of transmission between fully vaccinated individuals and may serve as a model for future investigations of large outbreaks.


    The size of the Provincetown outbreak—over one thousand cases—and its rapid early growth demonstrate that in densely crowded events and indoor conditions the SARS-CoV-2 Delta variant can cause a large outbreak even in a mostly vaccinated population. However, the Provincetown outbreak did not contribute substantially to the increase in Delta cases in Massachusetts. The high rates of vaccination and the swift public health response1, which included deployment of mobile testing, a local indoor masking mandate, and an extensive outreach campaign, likely contributed to the short duration and restricted impact of the outbreak. Additionally, the active engagement of the affected community in the epidemiological response, possibly influenced by historical public health outreach in the gay community, may have helped mitigate the impact of the outbreak15. The rapid decline and limited impact of the outbreak suggest that while Delta-driven outbreaks are not eliminated by high vaccination rates, they can be controlled with well-understood public health measures.

    WOW an anti parasitic that shows anti viral tendency, can you believe it??? WOW!!!


    Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern


    https://pubs.acs.org/doi/full/10.1021/acsinfecdis.1c00278


    Abstract


    The antimicrobial medication malarone (atovaquone/proguanil) is used as a fixed-dose combination for treating children and adults with uncomplicated malaria or as chemoprophylaxis for preventing malaria in travelers. It is an inexpensive, efficacious, and safe drug frequently prescribed around the world. Following anecdotal evidence from 17 patients in the provinces of Quebec and Ontario, Canada, suggesting that malarone/atovaquone may present some benefits in protecting against COVID-19, we sought to examine its antiviral potential in limiting the replication of SARS-CoV-2 in cellular models of infection. In VeroE6 expressing human TMPRSS2 and human lung Calu-3 epithelial cells, we show that the active compound atovaquone at micromolar concentrations potently inhibits the replication of SARS-CoV-2 and other variants of concern including the alpha, beta, and delta variants. Importantly, atovaquone retained its full antiviral activity in a primary human airway epithelium cell culture model. Mechanistically, we demonstrate that the atovaquone antiviral activity against SARS-CoV-2 is partially dependent on the expression of TMPRSS2 and that the drug can disrupt the interaction of the spike protein with the viral receptor, ACE2. Additionally, spike-mediated membrane fusion was also reduced in the presence of atovaquone. In the United States, two clinical trials of atovaquone administered alone or in combination with azithromycin were initiated in 2020. While we await the results of these trials, our findings in cellular infection models demonstrate that atovaquone is a potent antiviral FDA-approved drug against SARS-CoV-2 and other variants of concern in vitro.


    Discussion


    This study demonstrates that the antimicrobial drug atovaquone inhibits SARS-CoV-2 infection and replication in vitro as well as prevents the expression of associated inflammatory markers in human lung infected cells. Mechanistically, we show that atovaquone may interfere with the binding of the spike protein and the human receptor ACE2 during the entry phase. We also demonstrate a probable partial requirement for TMPRSS2 in driving the antiviral effect of the drug. Finally, our experiments also suggest an intracellular action of the drug on virus replication through a mechanism yet to be determined but not involving mitochondrial dysfunction and inhibition of the purine or pyrimidine biosynthesis pathways. Importantly, atovaquone is an FDA-approved, well-tolerated, and orally available drug currently in use for the treatment of different infectious diseases. Together with the anecdotal observations of the possible beneficial effects of the drug in Canadian patients, combined with our in vitro data on its antiviral activity against several variants of concern and in the primary lung epithelium cell culture model, the findings presented here suggest that atovaquone could provide benefits and may easily be repurposed. We are now awaiting the results from the clinical trials initiated in the USA where atovaquone was administered alone or in combination with azithromycin to confirm whether this medication is a good candidate as an inhibitor of SARS-CoV-2 replication and inflammation-induced pathology in COVID-19 patients.

    Since the emergence of SARS-CoV-2 and the beginning of the global pandemic in December 2019, tremendous scientific and technological advances have been made in developing safe and efficacious vaccine candidates. (1−4) However, challenges in vaccine distribution and availability as well as the emergence of new variants could mean that reaching the necessary levels of immunity to suppress SARS-CoV-2 will still take a considerable amount of time. This further highlights the important need for the continued research and development of antivirals, which can protect individuals from developing severe COVID-19, in the absence of immunization. Furthermore, high-fatality coronavirus outbreaks have now been reported roughly every 10 years since the identification of SARS in China in 2002 followed by the MERS epidemic in Saudi Arabia in 2012. Given the zoonotic nature of these viral outbreaks, a future coronavirus pandemic is extremely likely, and therefore, developing broadly acting antivirals or repurposing already clinically approved drugs against coronaviruses should be of the highest priority for public health.

    Our study focused on uncovering the potential antiviral effect of atovaquone in vitro. In cellular models of infection, our experiments showed promising and significant dose-dependent block in the infectivity of replicative wtVSV and VSV-spike in different types of VeroE6 cells expressing hACE2 and/or hTMPRSS2. Furthermore, we confirmed that the antiviral action of atovaquone was retained against both the ancestral SARS-CoV-2 and other variants of concern in similar cellular testing systems. However, a recent study from Dittmar et al. highlighted the importance of validating drug candidates in relevant human lung epithelial cells. Their study identified major differences in drug sensitivity and entry pathways used by SARS-CoV-2 in different cell types. For instance, entry in lung epithelial Calu-3 cells was shown to be pH-independent and required TMPRSS2, while entry in Vero and Huh7.5 cells required low pH and was rather triggered by acid-dependent endosomal proteases. (28) Thus, we extended our studies to lung epithelial Calu-3 cells and found that atovaquone still displayed high antiviral activity against SARS-CoV-2 without affecting the cellular viability in this particularly relevant in vitro system. Even more importantly, the antiviral action of atovaquone was fully retained against the SARS-CoV-2 alpha variant in the primary human airway lung epithelium culture model.

    One study which employed large-scale screening of FDA-approved drugs to identify promising SARS-CoV-2 antivirals identified quinones as useful agents to inhibit infectious SARS-CoV-2 production. (29) In addition, a current preprint described atovaquone as a particularly promising agent due to its covalent binding to the SARS-CoV-2 main protease enzyme (Mpro), which suggests that the antiviral effects are durable. (23) Our study identified atovaquone as a drug with a possible multimodal action on the virus, which can act both prophylactically and therapeutically in vitro; mechanistically, we report a modest but significant reduction in the binding between the spike S1 domain and ACE2 and demonstrate a dependency on TMPRSS2 in driving atovaquone-mediated antiviral effects against SARS-CoV-2. Additionally, atovaquone slightly impaired the fusion process as measured experimentally in an in vitro assay. Previous studies reported that TMPRSS2 can also cleave the ACE2 receptor and thus limit its surface expression. (30) Although atovaquone was unable to inhibit the TMPRSS2 activity in an in vitro assay using a peptide substrate, it is unknown whether similar results would be obtained with other substrates such as ACE2. Therefore, it would be pertinent to assess in future studies whether the atovaquone-induced antiviral activity could result from cleavage of ACE2 through the TMPRSS2-mediated proteolytic activity.

    Altogether our data provide some hints as to how the drug affects the entry step of the virus. We also show that atovaquone can act at the postentry step and affect the intracellular phase of viral replication through a modality of action yet to be determined but not involving the alteration of the mitochondrial function or the synthesis of purine or pyrimidines by the molecule.

    Altogether, our study reports atovaquone as a potent in vitro antiviral agent against SARS-CoV-2 and highlights that results from future efficacy studies in clinical trials in humans are needed to determine whether the drugs identified here could be used alone or in combination as a treatment for COVID-19

    Isn't it nice that science finally catches up with the farmer. I posted studies over a year ago pointing to bad gut. Huxley thought that wasn't good science. I suggested checking your body pH, I was told by same member I was nuts. I stand vindicated!!!


    UMass Chan study finds association between long-COVID symptoms and altered oral microbiome


    UMass Chan study finds association between long-COVID symptoms and altered oral microbiome
    Research by John P. Haran, MD, PhD, and Evan S. Bradley, MD, PhD, at UMass Chan Medical School, shows that patients with persistent long-COVID symptoms have…
    www.umassmed.edu


    Research by John P. Haran, MD, PhD, and Evan S. Bradley, MD, PhD, at UMass Chan Medical School, shows that patients with persistent long-COVID symptoms have oral microbiomes with a significantly higher abundance of bacteria that induce inflammation. These findings suggest an association between the oral microbiome and long COVID that may point to dysfunction in the oral microbiome as a contributor to long COVID.


    “We don’t understand the mechanism of long COVID. Nobody knows how or why it happens,” said Dr. Haran, associate professor of emergency medicine and microbiology & physiological systems and clinical director of the Center for Microbiome Research at UMass Chan. “There are suggestions that the innate immune system may be overstimulated from COVID. It’s not clear why, but after SARS-CoV-2 has cleared, the immune system seems to still be active. What we found is a clear biological signal associating a change in the oral microbiome with long-COVID symptoms. This suggests that the microbiome might be playing a part in long COVID and is a mechanism that deserves more study.”


    Like the microbiomes found in the gut and on the skin, the oral microbiome is a collection of bacteria that can affect the progression of health and disease. Much smaller than the gut microbiome, the oral microbiome comprises a few hundred different species of bacteria. It is the first meeting place along the alimentary canal, the passage along which food passes from the mouth through the body and where the immune system meets the outside world.


    It’s believed that maintaining the delicate balance of the oral microbiome can play an important part in health. An imbalance in the oral microbiome can lead to inflammation, illness and disease. Imbalances in the oral microbiome have been associated with chronic gum disease and can also impact the health of the gut microbiome.


    “The microbiome in our mouths is something we live in balance with every day,” said Haran. “The innate immune system keeps it running smoothly. Disrupting this balance can impact the innate immune system and through it, health and disease. For patients suffering from long-COVID symptoms, the microbiome changes to a very pro-inflammatory state.”


    Study co-author Dr. Bradley, assistant professor of emergency medicine, explained that it’s not clear what the differences seen in the microbiome of long-COVID patients reflect. “We believe that the oral microbiome influences how an individual’s immune system responds to COVID and so a pro-inflammatory microbiome could lead to prolonged symptoms even after the virus is cleared. It’s also possible that in some individuals, COVID drives a change in the microbiome toward a pro-inflammatory profile, which leads to prolonged symptoms.”


    Only recently recognized as a diagnosis, long COVID is defined as symptoms that can’t be explained by another cause, continuing for more than 10 weeks after an acute infection of COVID has passed. The SARS-CoV-2 virus is no longer present, but patients continue to suffer from a range of ailments like headaches, extreme fatigue and changes in their memory and their thinking, as well as muscle weakness and joint pain and muscle aches.


    “Something else is going on besides the SARS-CoV-2 virus and its not clear why these people are getting sick,” said Haran. “For people that have had the vaccine and subsequently get COVID, it doesn’t appear that the vaccine protects against long COVID either.”


    To study the connection between long COVID and the oral microbiome, Haran and Bradley sampled 164 patients presenting in the emergency room with COVID over a nine-month period. Blood and oral swabs were taken from patients, who were also tested for COVID. Eighty-four of the 164 tested positive for COVID by PCR and were admitted to the hospital for treatment. Of these, 27 were successfully contacted for follow up at both four weeks and 10 weeks. Fourteen patients from this group experienced ongoing symptoms four weeks from disease onset and 10 patients had symptoms for longer than 10 weeks. On average, patients experienced 45.8 days of symptoms.


    Haran and Bradley used whole genome sequencing and advanced algorithms to identify the composition of bacteria in the oral microbiome among patients experiencing prolonged symptoms. Of the hundreds of bacteria species identified, 19 were seen in abundance in those patients with ongoing symptomatic COVID-19 that didn’t appear in other patients.


    There has been a growing concern that long-COVID patients resemble patients with myalgic encephalomyelitis/chronic fatigue syndrome. These two conditions share some of the same symptoms, especially fatigue and cognitive impairment. Myalgic encephalomyelitis/chronic fatigue syndrome is a condition characterized by chronic fatigue, lasting at least six months, that impairs one’s ability to perform daily activities and typically has additional impairments in memory and concentration. This syndrome is also linked closely to chronic inflammation as the driver of these patients’ symptoms.


    “There’s an association between the oral microbiome, inflammation and long COVID that we don’t understand,” said Haran. “In trying to understand, prevent and treat long COVID, this association is something that needs to be explored more thoroughly. For that, we need a larger, longitudinal study with more volunteers and more data.”

    Targeting the Microbiome With KB109 in Outpatients with Mild to Moderate COVID-19 Reduced Medically Attended Acute Care Visits and Improved Symptom Duration in Patients With Comorbidities


    Targeting the Microbiome With KB109 in Outpatients with Mild to Moderate COVID-19 Reduced Medically Attended Acute Care Visits and Improved Symptom Duration in Patients With Comorbidities
    Introduction In 2020, the world experienced the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as the coronavirus…
    doi.org



    Abstract

    Introduction In 2020, the world experienced the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as the coronavirus disease 2019 (COVID-19) pandemic. Mounting evidence indicates that the gut microbiome plays a role in host immune response to infections and, in turn, may have an impact on the disease trajectory of SARS-CoV2 infection. However, it remains to be established whether modulation of the microbiome can impact COVID-19–related symptomatology and patient outcomes. Therefore, we conducted a study designed to modulate the microbiome evaluating the safety and physiologic effects of KB109 combined with self-supportive care (SSC) vs SSC alone in non-hospitalized patients with mild to moderate COVID-19. KB109 is a novel synthetic glycan developed to increase the production of gut microbial metabolites that support immune system homeostasis through gut microbiome modulation. Our goal was to gain a better understanding of the safety of KB109, the natural course of COVID-19 symptomatology, and the possible role of the gut microbiome in patients with mild to moderate COVID-19.


    Methods Adult patients who tested positive for COVID-19 were randomized 1:1 to receive KB109 combined with SSC or SSC alone for 14 days and were then followed for an additional 21 days (35 days in total). Patients self-assessed their COVID-19–related symptoms (8 cardinal symptoms plus 5 additional symptoms) and self-reported comorbidities. The primary and secondary objectives were to evaluate the safety of KB109 plus SSC compared with that of SSC alone and to evaluate selected measures of health, respectively.


    Results Between July 2, 2020 and December 23, 2020, 350 patients were randomized to receive KB109 and SSC (n=174) or SSC alone (n=176). Overall, the most common comorbidities reported were hypertension (18.0% [63/350 patients]) followed by chronic lung disease (8.6% 30/350 patients). KB109 was well tolerated with most treatment-emergent adverse events being mild to moderate in severity. The administration of KB109 plus SSC reduced medically-attended visits (ie, hospitalization, emergency room visits, or urgent care visits) by 50.0% in the overall population and by 61.7% in patients with ≥1 comorbidity; in patients aged ≥45 years or with ≥1 comorbidity, medically-attended visits were reduced by 52.8%, In the SSC group, patients reporting ≥1 comorbidity had a longer median time to resolution of symptoms than those who reported no comorbidities at baseline (13 overall symptoms: 30 vs 21 days, respectively; hazard ratio [HR]=1.163 [95% CI, 0.723-1.872]; 8 cardinal symptoms: 21 vs 15 days, respectively; HR=1.283 [95% CI, 0.809-2.035]). In patients reporting ≥1 comorbidity, median time to resolution of symptoms was shorter in the KB109 plus SSC group compared with the SSC alone group (13 overall symptoms: 30 vs 21 days, respectively; HR=1.422 [95% CI, 0.898-2.250]; 8 cardinal symptoms: 17 vs 21 days, respectively; HR=1.574 [95% CI, 0.997-2.485]). In the KB109 plus SSC group, patients aged ≥45 years or with ≥1 comorbidity had a shorter median time to resolution of symptoms compared with SSC alone (overall 13 symptoms: 21 vs 31 days; HR=1.597 [95% CI, 1.064-2.398]).


    Conclusions Results from our study show that KB109 is well tolerated among patients with mild to moderate COVID-19. Patients with ≥1 comorbidity had a longer duration of COVID-19 symptoms than those without comorbidities. Moreover, in patients reporting ≥1 comorbidity or aged ≥45 years (at-risk population), administration of KB109 plus SSC improved median time to resolution of COVID-19–related symptoms and reduced the rate of medically-attended visits compared with SSC alone.



    The FDA refuses to recognize results based on KB109 not being a food. It's made from sugars of fruit!

Subscribe to our newsletter

It's sent once a month, you can unsubscribe at anytime!

View archive of previous newsletters

* indicates required

Your email address will be used to send you email newsletters only. See our Privacy Policy for more information.

Our Partners

Supporting researchers for over 20 years
Want to Advertise or Sponsor LENR Forum?
CLICK HERE to contact us.